Detection of a Parkinson's Disease-Specific MicroRNA Signature in Nasal and Oral Swabs.
Lewy body disease
Parkinson's disease
biomarker
microRNA
oral and nasal swab
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
11
05
2023
received:
17
02
2023
accepted:
31
05
2023
medline:
19
9
2023
pubmed:
29
6
2023
entrez:
29
6
2023
Statut:
ppublish
Résumé
Biomaterials from oral and nasal swabs provide, in theory, a potential resource for biomarker development. However, their diagnostic value has not yet been investigated in the context of Parkinson's disease (PD) and associated conditions. We have previously identified a PD-specific microRNA (miRNA) signature in gut biopsies. In this work, we aimed to investigate the expression of miRNAs in routine buccal (oral) and nasal swabs obtained from cases with idiopathic PD and isolated rapid eye movement sleep behavior disorder (iRBD), a prodromal symptom that often precedes α-synucleinopathies. We aimed to address their value as a diagnostic biomarker for PD and their mechanistic contribution to PD onset and progression. Healthy control cases (n = 28), cases with PD (n = 29), and cases with iRBD (n = 8) were prospectively recruited to undergo routine buccal and nasal swabs. Total RNA was extracted from the swab material, and the expression of a predefined set of miRNAs was quantified by quantitative real-time polymerase chain reaction. Statistical analysis revealed a significantly increased expression of hsa-miR-1260a in cases who had PD. Interestingly, hsa-miR-1260a expression levels correlated with diseases severity, as well as olfactory function, in the PD and iRBD cohorts. Mechanistically, hsa-miR-1260a segregated to Golgi-associated cellular processes with a potential role in mucosal plasma cells. Predicted hsa-miR-1260a target gene expression was reduced in iRBD and PD groups. Our work demonstrates oral and nasal swabs as a valuable biomarker pool in PD and associated neurodegenerative conditions. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
Biomaterials from oral and nasal swabs provide, in theory, a potential resource for biomarker development. However, their diagnostic value has not yet been investigated in the context of Parkinson's disease (PD) and associated conditions.
OBJECTIVE
We have previously identified a PD-specific microRNA (miRNA) signature in gut biopsies. In this work, we aimed to investigate the expression of miRNAs in routine buccal (oral) and nasal swabs obtained from cases with idiopathic PD and isolated rapid eye movement sleep behavior disorder (iRBD), a prodromal symptom that often precedes α-synucleinopathies. We aimed to address their value as a diagnostic biomarker for PD and their mechanistic contribution to PD onset and progression.
METHODS
Healthy control cases (n = 28), cases with PD (n = 29), and cases with iRBD (n = 8) were prospectively recruited to undergo routine buccal and nasal swabs. Total RNA was extracted from the swab material, and the expression of a predefined set of miRNAs was quantified by quantitative real-time polymerase chain reaction.
RESULTS
Statistical analysis revealed a significantly increased expression of hsa-miR-1260a in cases who had PD. Interestingly, hsa-miR-1260a expression levels correlated with diseases severity, as well as olfactory function, in the PD and iRBD cohorts. Mechanistically, hsa-miR-1260a segregated to Golgi-associated cellular processes with a potential role in mucosal plasma cells. Predicted hsa-miR-1260a target gene expression was reduced in iRBD and PD groups.
CONCLUSIONS
Our work demonstrates oral and nasal swabs as a valuable biomarker pool in PD and associated neurodegenerative conditions. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Substances chimiques
MicroRNAs
0
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1706-1715Informations de copyright
© 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Références
Ahmadi S-A et al. Analyzing the co-localization of substantia nigra hyper-echogenicities and iron accu'ulation in Parkinson's disease: a multi-modal atlas study with transcranial ultrasound and MRI. Neuroimage Clin 2020;26:102185.
Postuma RB, Berg D. Advances in markers of prodromal Parkinson disease. Nat Rev Neurol 2016;12:622-634.
Berg D, Marek K, Ross GW, Poewe W. Defining at-risk popu'ations for Parkinson's disease: lessons from ongoing studies. Mov Disord 2012;27:656-665.
Berg D, Yao C, Pelletier A, Montplaisir JY, Gagnon JF, Postuma RB. Prodromal Parkinson disease subtypes - key to understanding heterogeneity. Nat Rev Neurol 2021;17:349-361.
Fereshtehnejad S-M et al. Evolution o’ prodromal Parkinson's disease and dementia with Lewy bodies: a prospective study. Brain 2019;142:2051-2067.
Schrag A, Horsfall L, Walters K, Noyce A, Petersen I. Prediagnostic prese'tations of Parkinson's disease in primary care: a case-control study. Lancet Neurol 2015;14:57-64.
Iranzo A et al. Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. Lancet Neurol 2021;20:203-212.
Galbiati A, Verga L, Giora E, Zucconi M, Ferini-Strambi L. The risk of neurodegeneration in REM sleep behavior disorder: a systematic review and meta-analysis of longitudinal studies. Sleep Med Rev 2019;43:37-46.
Greffard S et al. Motor score of the unified Parkinson disease rating scale as a good predictor of Lewy body-associated neuronal loss in the substantia Nigra. Arch Neurol 2006;63:584-588.
Kordower JH et al. Disease duration and the integrity of the nigrostriata’ system in Parkinson's disease. Brain 2013;136:2419-2431.
Chu Y, Buchman AS, Olanow CW, Kordower JH. Do subjects with minimal motor features have prodromal Parkinson disease? Ann Neurol 2018;83:562-574.
Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.
Fairfoul G, McGuire LI, Pal S, et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol 2016;3:812-818.
Bargar C, Wang W, Gunzler SA, et al. Streamlined alpha-synuclein RT-QuIC assay for various bios'ecimens in Parkinson's disease and dementia with Lewy bodies. Acta Neuropathol Commun 2021;9:62.
Liu X, Yang J, Yuan Y, et al. Optimization of the detection method for phosphorylated α-synuclein in Parkinson disease by skin biopsy. Front Neurol 2020;11:569446.
Stefani A, Iranzo A, Holzknecht E, et al. Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder. Brain 2021;144(4):1118-1126.
Iranzo A, Mammana A, Muñoz-Lopetegi A, et al. Misfolded α-synuclein assessment in skin and CSF by RT-QuIC in isolated REM sleep behavior disorder. Neurology 2023;100(18):e1944-e1954. https://doi.org/10.1212/wnl.0000000000207147
Soto M, Iranzo A, Lahoz S, et al. Serum MicroRNAs predict isolated rapid eye movement sleep behavior disorder and Lewy body diseases. Mov Disord 2022;37:2086-2098.
Kurz A, Kumar R. Differential expression of gut miRNAs in'idiopathic Parkinson's disease. Parkinsonism Relat Disord 2021;88:46-50.
Kobal G, Hummel T, Sekinger B, Barz S, Roscher S, Wolf S. “Sniffin’ sticks”: screening of olfactory performance. Rhinology 1996;34:222-226.
Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006;130:1480-1491.
Stiasny-Kolster K, Mayer G, Schäfer S, Möller JC, Heinzel-Gutenbrunner M, Oertel WH. The REM sleep behavior disorder screening questionnaire-a new diagnostic instrument. Mov Disord 2007;22:2386-2393.
Wang X, Spandidos A, Wang H, Seed B. PrimerBank: a PCR primer database for quantitative gene expression analysis, 2012 update. Nucleic Acids Res 2012;40:D1144-D1149.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔC T method. Methods 2001;25:402-408.
Chen Y, Wang X. miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res 2019;48:D127-D131.
Kuleshov, M. V. Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, Koplev S, Jenkins SL, Jagodnik KM, Lachmann A, McDermott MG, Monteiro CD’ Gundersen GW, Ma'ayan A. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res 44, W90-W97 (2016).
Williams DW, Greenwell-Wild T, Brenchley L, et al. Human oral mucosa cell atlas reveals a stromal-neutrophil axis regulating tissue immunity. Cell 2021;184:4090-4104.e15.
Hao Y, Hao S, Andersen-Nissen E, et al. Integrated analysis of multimodal single-cell data. Cell 2021;184:3573-3587.e29.
Credle JJ, Forcelli PA, Delannoy M, et al. α-Synuclein-mediated inhibition of ATF6 processing into COPII vesicles disrupts UPR s'gnaling in Parkinson's disease. Neurobiol Dis 2015;76:112-125.
Latourelle JC, Pankratz N, Dumitriu A, et al. Genomewide association study for onset age in Parkinson disease. BMC Med Genet 2009;10:98.
Rayaprolu S, Fujioka S, Traynor S, et al. TARDBP m'tations in Parkinson's disease. Parkinsonism Relat Disord 2013;19:312-315.
Pollitt AY, Insall RH. Wasp and SCAR/WAVE proteins: the drivers of Actin assembly. J Cell Sci 2009;122:2575-2578.
Miglis MG, Adler CH, Antelmi E, et al. Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder. Lancet Neurol 2021;20:671-684.
Kurz A, Kumar R, Northoff BH, et al. Differential expression of gut miRNAs in'idiopathic Parkinson's disease. Parkinsonism Relat Disord 2021;88:46-50.
Dobricic V, Schilling M, Schulz J, et al. Differential microRNA expression analyses across two brain'regions in Alzheimer's disease. Transl Psychiatry 2022;12:352.
Dauvilliers Y, Schenck CH, Postuma RB, et al. REM sleep behaviour disorder. Nat Rev Dis Primers 2018;4:19.
Alibiglou L, Videnovic A, Planetta PJ, Vaillancourt DE, MacKinnon CD. Subliminal gait initiation deficits in rapid eye movement sleep behavior disorder: a harbinger of freezing of gait? Mov Disord 2016;31:1711-1719.
Postuma RB, Lang AE, Gagnon JF, Pelletier A, Montplaisir JY. How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. Brain 2012;135:1860-1870.
Postuma RB, Gagnon JF, Vendette M, Montplaisir JY. Markers of neurodegeneration in idiopathic rapid eye movement sleep behaviour d'sorder and Parkinson's disease. Brain 2009;132:3298-3307.
Farr RJ, Rootes CL, Stenos J, Foo CH, Cowled C, Stewart CR. Detection of SARS-CoV-2 infection by microRNA profiling of the upper respiratory tract. Plos One 2022;17:e0265670.
Latini A, Vancheri C, Amati F, et al. ExpressiIanalysis of miRNA hsa-let7b-5p in naso-oropharyngeal swabs of COVID-19 patients supports its role in regulating ACE2 and DPP4 receptors. J Cell Mol Med 2022;26:4940-4948.
Girard V, Goubard V, Querenet M, et al. Spen modulates lipid droplet content in adult drosophila glial cells and protects against paraquat toxicity. Sci Rep 2020;10:20023.
Yun SP, Kam TI, Panicker N, et al. Block of A1 astrocyte conversion by microglia is neuroprotectiv’ in models of Parkinson's disease. Nat Med 2018;24:931-938.
Pyke C, Heller RS, Kirk RK, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 2014;155:1280-1290.
Infante J, Prieto C, Sierra M, et al. Identification of candi'ate genes for Parkinson's disease through blood transcriptome analysis in LRRK2-G2019S carriers, idiopathic cases, and controls. Neurobiol Aging 2015;36:1105-1109.
Nguyen TPN, Kumar M, Fedele E, Bonanno G, Bonifacino T. MicroRNA alteration, application as biomarkers, and therapeutic approaches in neurodegenerative diseases. Int J Mol Sci 2022;23:4718.
Santos-Lobato BL, Vidal AF, Ribeiro-dos-Santos Â. Regulatory miRNA-mRN’ networks in Parkinson's disease. Cell 2021;10:1410.
Li S, Liu L, Zhuang X, et al. MicroRNAs inhibit the translation of target mRNAs on the endoplasmic reticulum in Arabidopsis. Cell 2013;153:562-574.
Bartl M, Xylaki M, Bähr M, Weber S, Trenkwalder C, Mollenhauer B. Evidence for immune system alterations in peripheral biolog'cal fluids in Parkinson's disease. Neurobiol Dis 2022;170:105744.
Schwienbacher C, Foco L, Picard A, et al. Plasma and white blood cells show different miRNA expressio’ profiles in Parkinson's disease. J Mol Neurosci 2017;62:244-254.
Scott KM. B l'ymphocytes in Parkinson's disease. J Parkinsons Dis 2022;12:S75-S81.
Chen S, Le WD XWJ, Alexianu ME, Engelhardt JI, Siklós L, Appel SH. Experimental destruction of substantia Nigra initiated by Parkinson disease immunoglobulins. Arch Neurol 1998;55:1075-1080.
Stevens CH, Rowe D, Morel-Kopp MC, et al. Reduced T helper and B ’ymphocytes in Parkinson's disease. J Neuroimmunol 2012;252:95-99.
Bas J, Calopa M, Mestre M, Mollevı DG, Cutillas B, Ambrosio S, Buendia E. Lymphocyte ’opulations in Parkinson's disease and in rat models of parkinsonism. J Neuroimmunol 2001;113:146-152.
Gruden MA, Sewell RD, Yanamandra K, et al. Immunoprotection against toxic biomarkers is r'tained during Parkinson's disease progression. J Neuroimmunol 2011;233:221-227.
Kobo H, Bar-Shira A, Dahary D, et al. Down-regulation of B cell-related genes in peripheral blood'leukocytes of Parkinson's disease patients with and without GBA mutations. Mol Genet Metab 2016;117:179-185.
Cook DA, Kannarkat GT, Cintron AF, et al. LRRK2 levels in immune cells ar’ increased in Parkinson's disease. NPJ Parkinsons Dis 2017;3:11.
Kubo M, Nagashima R, Ohta E, et al. Leucine-rich repeat kinase 2 is a regulator of B cell function, affecting homeostasis, BCR signaling, IgA production, and TI antigen responses. J Neuroimmunol 2016;292:1-8.
Akhtar RS, Licata JP, Luk KC, Shaw LM, Trojanowski JQ, Lee VM. Measurements of auto-antibodies to α-synuclein in the serum and cerebral spinal fluids of'patients with Parkinson's disease. J Neurochem 2018;145:489-503.
Horvath I, Iashchishyn IA, Forsgren L, Morozova-Roche LA. Immunochemical detection of α-synuclein aut'antibodies in Parkinson's disease: correlation between plasma and cerebrospinal fluid levels. ACS Chem Nerosci 2017;8:1170-1176.
Shalash A, Salama M, Makar M, et al. Elevated serum α-synuclein autoantibodies in ’atients with Parkinson's diseas’ relative to Alzheimer's disease and controls. Front Neurol 2017;8:720.
Brochard V, Combadière B, Prigent A, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 2009;119:182-192.
Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM. A possible role for humoral immunity in the p'thogenesis of Parkinson's disease. Brain 2005;128:2665-2674.
Benner EJ, Banerjee R, Reynolds AD, et al. Nitrated α-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PloS One 2008;3:e1376.
Jankovic J, Goodman I, Safirstein B, et al. Safety and tolerability of multiple ascending doses of PRX002/RG7935, an anti-α-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial. JAMA Neurol 2018;75:1206.
Horsager J, Andersen KB, Knudsen K, et al. Brain-first ver'us body-first Parkinson's disease: a multimodal imaging case-control study. Brain 2020;143:3077-3088.
Moutsopoulos NM, Konkel JE. Tissue-specific immunity at the Oral mucosal barrier. Trends Immunol 2018;39:276-287.
Rezende RM, Weiner HL. History and mechanisms of oral tolerance. Semin Immunol 2017;30:3-11.